DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1808)

34 Biopharma Reports

  • malignant melanoma
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite...
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28......
TreatmentTrends®: Malignant Melanoma Q2 2015 (US) is the first in a series of...
TreatmentTrends®: Malignant Melanoma Q2 2015 (US) is the first in a series of reports that examines current trends in the management of unresectable or metastatic malignant melanoma from the perspe......
Oncology indications increasingly use predictive biomarkers to guide prescribing...
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Brazil is highly dependent on incorporation into priva......
Oncology indications increasingly use predictive biomarkers to guide prescribing...
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their inco......
The success of an anticancer therapy is not only dependent on the outcome of...
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and pres...
1 - 20 of 34